UNIWERSYTET MEDYCZNY IM KAROLA MARCINKOWSKIEGO W POZNANIU

Their core work

Poznań University of Medical Sciences is a Polish medical university with strong capabilities in paediatric health research, pharmaceutical sciences, and clinical trials. They contribute epidemiological expertise to large European cohort studies on birth defects, neonatal brain injury, and preterm infant outcomes. They also run a significant training programme in biopharmaceutics and drug delivery (ORBIS), and have recently expanded into medical device regulation and peritoneal dialysis research.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2017), the university focused on clinical paediatric health — preterm infant screening, neonatal brain injury, and assisted living for elderly patients. From 2018 onward, their profile broadened significantly: they took on coordination of a pharmaceutical sciences training network (ORBIS), entered the medical device regulation space (MDOT), and joined nephrology research (IMPROVE-PD). This shift suggests a deliberate expansion from purely clinical research toward pharmaceutical technology, regulatory science, and translational medicine.

Moving from clinical observation studies toward applied pharmaceutical R&D and medical device regulation — increasingly positioned at the research-to-market translation boundary.

How they like to work

Primarily a consortium participant (5 of 7 projects), stepping into coordination once with ORBIS — a training-focused MSCA network. With 115 unique partners across 25 countries, they are well-connected across European health research networks. Their wide partner base and diverse project types suggest they are a flexible, reliable consortium member rather than a project-driving hub.

Extensive European network spanning 115 unique partners in 25 countries, reflecting deep integration into multi-country clinical studies and training programmes. Geographic reach is pan-European with no apparent regional concentration.

What sets them apart

They combine clinical medical research with pharmaceutical technology expertise — a relatively rare pairing in Polish academia. Their ORBIS coordination demonstrates capacity to lead international training in drug delivery and biopharmaceutics, while their MDOT participation brings practical knowledge of medical device regulation under the new EU MDR. For consortium builders, they offer a Polish partner with both clinical trial infrastructure and pharmaceutical sciences depth.

Highlights from their portfolio

• ORBIS
  Their only coordinated project — a MSCA training network in biopharmaceutics and drug delivery, signalling institutional commitment to pharmaceutical sciences.
• MDOT
  Largest single funding (EUR 897K) and an unusual pivot into medical device regulation, blockchain-based safety databases, and MDR compliance.
• EUROlinkCAT
  Major European birth defect cohort study linking registry data with hospital records across multiple countries — core epidemiological infrastructure work.